Related Experiment Video
Updated: May 14, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Continuous C-peptide loss in patients with type 1 diabetes and multiethnic background
Joana R Dantas1, Mirella H Almeida, Bianca Barone
1Nutrology Department, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro (HUCFF), Rio de Janeiro, RJ, Brazil. joanardantasp@ig.com.br
Abstract:
C peptide (CP) was evaluated in 88 individuals with type 1 diabetes, variable disease duration and multiethnic background. Initially, 28 patients had detectable CP, which persisted in 46.2% after 17.4±4 months. CP decline was associated with ethnicity, HbA1c and baseline CP, but not with GADA, PTPN22 or insulin gene polymorphisms.
Related Concept Videos
Type I Diabetes III: Clinical Manifestations
Type I Diabetes II: Pathophysiology
Type I Diabetes I: Introduction
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

